Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 5/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15461691 | 0.79 | GAA (0.36) | SLC29A1CRHR1GAAHTTTDP1 | |
| SCHEMBL13377948 | 0.67 | HPGD (0.39) | TDP1ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL1035062 | 0.63 | SLC29A1 (0.58) | SLC29A1GAATDP1ALDH1A1MAPT | |
| SCHEMBL12449940 | 0.61 | GAA (0.40) | SLC29A1GAAHTTMAPTSMN1; SMN2 | |
| SCHEMBL22382 | 0.60 | ALDH1A1 (0.55) | TDP1ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL13567348 | 0.60 | GAA (0.39) | SLC29A1GAAHTTKDM4E | |
| SCHEMBL13377995 | 0.58 | TSHR (0.41) | TDP1ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL28726114 | 0.58 | ALDH1A1 (0.52) | TDP1ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL12169523 | 0.56 | SLC29A1 (0.64) | SLC29A1GAAHTTTDP1ALDH1A1 | |
| Trolamine SCHEMBL5874273 | 0.56 | ALOX15 (0.46) | TDP1MAPTSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351274-B2 | Methods of using optical agents | MEDIBEACON INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220127237-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MEDIBEACON INC. | 2022-04-28 | — | — | US | disclosed |
| US-11185597-B2 | Process for using optical agents | MEDIBEACON, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-10695445-B2 | Methods of using optical agents | MEDIBEACON INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10617687-B2 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | MEDIBEACON INC. (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190192696-A1 | METHODS OF USING OPTICAL AGENTS | MALLINCKRODT LLC | 2019-06-27 | — | — | US | disclosed |
| US-20190192695-A1 | PROCESS FOR USING OPTICAL AGENTS | MALLINCKRODT LLC | 2019-06-27 | — | — | US | disclosed |
| US-20190022256-A1 | METHODS OF USING OPTICAL AGENTS | MALLINCKRODT LLC | 2019-01-24 | — | — | US | disclosed |
| US-20170298030-A9 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | Medibeacon, LLC | 2017-10-19 | — | — | US | disclosed |
| US-20160280666-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MEDIBEACON INC (US) | 2016-09-29 | — | — | US | disclosed |
| EP-1854790-B1 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | MALLINCKRODT INC (US) | 2011-08-31 | — | — | EP | disclosed |
| EP-1836175-B1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MALLINCKRODT INC (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-2135863-A1 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | Mallinckrodt, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2039688-A1 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | Mallinckrodt, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20090010851-A1 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function | MALLINCKRODT INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090010851-A1 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function | MALLINCKRODT INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20080312539-A1 | Methods of Using Optical Agents | MEDIBEACON, INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080312539-A1 | Methods of Using Optical Agents | MEDIBEACON, INC. | 2008-12-18 | — | — | US | disclosed |
| EP-1854790-A1 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | Mallinckrodt, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007106142-A2 | PROCESS FOR USING OPTICAL AGENTS | MALLINCKRODT INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127237-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | GLS, XDH, CYP4F12 | SLC29A1 1189/4885CRHR1 1478/4885GAA 3762/4885 |
| US-10617687-B2 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | GLS, CYP4F12, XDH | SLC29A1 1200/4885CRHR1 1406/4885GAA 3858/4885 |
| US-20160280666-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | GLS, CYP4F12, XDH | SLC29A1 1200/4885CRHR1 1406/4885GAA 3858/4885 |
| US-10695445-B2 | Methods of using optical agents | REN, ATP6V1B1, VHL | SLC29A1 2027/4885CRHR1 4617/4885GAA 1314/4885 |
| US-20170298030-A9 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | GLS, CYP4F12, XDH | SLC29A1 1200/4885CRHR1 1406/4885GAA 3858/4885 |
| US-20190022256-A1 | METHODS OF USING OPTICAL AGENTS | REN, ATP6V1B1, VHL | SLC29A1 2027/4885CRHR1 4617/4885GAA 1314/4885 |
| US-20190192695-A1 | PROCESS FOR USING OPTICAL AGENTS | REN, ATP6V1B1, VHL | SLC29A1 2675/4885CRHR1 4652/4885GAA 925/4885 |
| US-20090010851-A1 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function | GLS, CYP4F12, XDH | SLC29A1 1200/4885CRHR1 1406/4885GAA 3858/4885 |
| US-11185597-B2 | Process for using optical agents | REN, ATP6V1B1, VHL | SLC29A1 2675/4885CRHR1 4652/4885GAA 925/4885 |
| US-11351274-B2 | Methods of using optical agents | REN, ATP6V1B1, VHL | SLC29A1 2027/4885CRHR1 4617/4885GAA 1314/4885 |
| US-20190192696-A1 | METHODS OF USING OPTICAL AGENTS | REN, ATP6V1B1, VHL | SLC29A1 2027/4885CRHR1 4617/4885GAA 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.